|
Post by sportsrancho on Apr 13, 2020 22:36:47 GMT -5
Only ultra rapid acting inhaled insulin. Why do you say that? What non injectable insulins are promoted as “ultra rapid”? BIOCHAPERONE® LISPRO BIOCHAPERONE® LISPRO: A MORE PHYSIOLOGICAL ULTRA-RAPID INSULIN An ultra-rapid insulin is an insulin that has a more rapid absorption profile than the rapid-acting insulin analogs currently on the market, aiming to mimic the immediate secretion of insulin when a non-diabetic person eats a meal. www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
|
|
|
Post by mannmade on Apr 13, 2020 23:26:52 GMT -5
Now can the reps tell docs that AFREZZA is the ONLY ultra rapid acting insulin? That is the real question for me... GLTAL’s!!! Forgot to add also hope this means there was a label expansion and that it will be reflected in the SOC by the ADA.
|
|
|
Post by mannmade on Apr 13, 2020 23:27:37 GMT -5
Only ultra rapid acting inhaled insulin. Why do you say that? What non injectable insulins are promoted as “ultra rapid”? Apridia.
|
|
|
Post by rfogel on Apr 13, 2020 23:53:10 GMT -5
Only ultra rapid acting inhaled insulin. Why do you say that? What non injectable insulins are promoted as “ultra rapid”? Lilly is supposed to launch its ultra rapid insulin this year: diabetes.diabetesjournals.org/content/68/Supplement_1/1112-P"Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs"
|
|
|
Post by mannmade on Apr 14, 2020 0:13:32 GMT -5
Well as I recall they do not have a Compliance Officer anymore...
|
|
|
Post by itellthefuture777 on Apr 14, 2020 1:10:42 GMT -5
Class III drug labels including websites are approved by agency so..thats that..
|
|
|
Post by boomboom on Apr 14, 2020 1:56:20 GMT -5
Discuss. afrezza.com/I like it. Job well done. Much more user friendly, conveys many points much better, shows the uniqueness of Afrezza much better. Better website flow and easier to understand. I like the colorway. A+ This website may have improved but it is not A+ worthy. I am only referring to the desktop version right now. The first landing page has 15 different clickable links! How is a new customer suppose to navigate this? They should have these randomly assorted links consolidate into clearly titled drop down menus. It would make the landing page way more welcoming imo.
|
|
|
Post by itellthefuture777 on Apr 14, 2020 4:00:10 GMT -5
Discuss. afrezza.com/I like it. Job well done. Much more user friendly, conveys many points much better, shows the uniqueness of Afrezza much better. Better website flow and easier to understand. I like the colorway. A+ This website may have improved but it is not A+ worthy. I am only referring to the desktop version right now. The first landing page has 15 different clickable links! How is a new customer suppose to navigate this? They should have these randomly assorted links consolidate into clearly titled drop down menus. It would make the landing page way more welcoming imo. it's good enough..next
|
|
|
Post by sportsrancho on Apr 14, 2020 6:55:46 GMT -5
Discuss. afrezza.com/I like it. Job well done. Much more user friendly, conveys many points much better, shows the uniqueness of Afrezza much better. Better website flow and easier to understand. I like the colorway. A+ This website may have improved but it is not A+ worthy. I am only referring to the desktop version right now. The first landing page has 15 different clickable links! How is a new customer suppose to navigate this? They should have these randomly assorted links consolidate into clearly titled drop down menus. It would make the landing page way more welcoming imo. That sounds very reasonable, thank you for your opinion that’s why Mango put it up so we could all discuss it.
|
|
|
Post by mango on Apr 14, 2020 7:05:41 GMT -5
Why do you say that? What non injectable insulins are promoted as “ultra rapid”? Lilly is supposed to launch its ultra rapid insulin this year: diabetes.diabetesjournals.org/content/68/Supplement_1/1112-P"Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs" We have gone over this many times before. It is misleading for Lilly to call it that and I would not be surprised if FDA did not let them call it that—It's the same BS Novo pulled with Fiasp. They were calling it ultra rapid and then had to stop once it was approved by FDA. Lilly's new insulin has a time-action profile of fast acting RAAs.
|
|
|
Post by hellodolly on Apr 14, 2020 7:12:28 GMT -5
Discuss. afrezza.com/I like it. Job well done. Much more user friendly, conveys many points much better, shows the uniqueness of Afrezza much better. Better website flow and easier to understand. I like the colorway. A+ This website may have improved but it is not A+ worthy. I am only referring to the desktop version right now. The first landing page has 15 different clickable links! How is a new customer suppose to navigate this? They should have these randomly assorted links consolidate into clearly titled drop down menus. It would make the landing page way more welcoming imo. I found it very simple, straight forward and easy to navigate, pleasing to the eyes and functional.
|
|
|
Post by hellodolly on Apr 14, 2020 7:15:22 GMT -5
We have gone over this many times before. It is misleading for Lilly to call it that and I would not be surprised if FDA did not let them call it that—It's the same BS Novo pulled with Fiasp. They were calling it ultra rapid and then had to stop once it was approved by FDA. Lilly's new insulin has a time-action profile of fast acting RAAs. Forget non-injectable. Use 'only rapid acting inhaled' insulin and let's actually call it what it is. Then we don't have to debate or fall into the trap of arguing over rapid acting, although it is a worthy feature of Afrezza.
|
|
|
Post by cppoly on Apr 14, 2020 7:19:51 GMT -5
Ultra rapid is all over the website. I just wish there was a press release if they got a label change.
|
|
|
Post by sportsrancho on Apr 14, 2020 7:20:20 GMT -5
From regenmedprovider....@rozey1 @cryptobishop @itzafugazi “Ultra Rapid Acting Insulin has been used for Afrezza in medical literature since 2014. I’m not seeing any FDA or 3rd party reimbursement changes currently. ncbi.nlm.nih.gov/pmc/articl...” www.ncbi.nlm.nih.gov/pmc/articles/PMC4455463/
|
|
|
Post by mango on Apr 14, 2020 7:49:08 GMT -5
We have gone over this many times before. It is misleading for Lilly to call it that and I would not be surprised if FDA did not let them call it that—It's the same BS Novo pulled with Fiasp. They were calling it ultra rapid and then had to stop once it was approved by FDA. Lilly's new insulin has a time-action profile of fast acting RAAs. Forget non-injectable. Use 'only rapid acting inhaled' insulin and let's actually call it what it is. Then we don't have to debate or fall into the trap of arguing over rapid acting, although it is a worthy feature of Afrezza. If/when a new Ultra category is made it will be important then. It would be deceiving and misleading to put anything other than Afrezza in the Ultra class because all others that try to sneak in the Ultra Rapid are not truly ultra and have time-action profiles of fast acting RAAs.
|
|